Clinical Report: What Causes the Itch in Dermatitis?

Overview

This report highlights the role of the IL-31 and IL-33 cytokine axis in driving the intense itch associated with atopic dermatitis, emphasizing their contribution to the itch-scratch cycle and informing treatment strategies.

Background

Atopic dermatitis is a prevalent chronic inflammatory skin disease characterized by a compromised skin barrier and severe itching, significantly impacting patients' quality of life through symptoms such as skin damage, infections, and sleep disturbances. Recent research has identified a cytokine axis involving IL-31 and IL-33 that links immune activation to nerve signaling, elucidating the biological basis for itch severity.

Data Highlights

No numerical data provided in the source material.

Key Findings

• IL-33 is released by keratinocytes in response to skin injury, promoting type 2 immune responses.
• IL-31, produced by type 2 helper T cells, directly stimulates itch-sensing nerve fibers.
• Higher levels of IL-31 and IL-33 correlate with increased disease severity in atopic dermatitis.
• The IL-31/IL-33 axis contributes to a self-perpetuating itch-scratch cycle that exacerbates skin barrier disruption.
• New targeted therapies, including nemolizumab, aim to disrupt this cytokine signaling to alleviate itch.

Clinical Implications

Clinicians should consider the IL-31/IL-33 axis when assessing itch severity in atopic dermatitis, as it provides a clearer biological rationale for treatment selection. Monitoring these cytokines may enhance the understanding of therapeutic responses and guide the use of emerging treatments.

Conclusion

The interplay between IL-31 and IL-33 is crucial in understanding the mechanisms of itch in atopic dermatitis, offering potential pathways for targeted therapeutic interventions.

References

1. Dermatology and Therapy, Springer, 2026 -- Beyond the Skin: Assessing Itch in Atopic Dermatitis – Insights from UK Dermatologists. A Cross-Sectional Survey and Narrative Review
2. Ophthalmology Management, 2024 -- Atopic Dermatitis
3. Contact Lens Spectrum, 2017 -- AVOID THE ITCH
4. Atopic dermatitis clinical guideline, AAD -- Clinical Guidelines
5. Contact Lens Spectrum — Ditch the Itch: Managing Allergy and Lens Wear
6. Atopic dermatitis clinical guideline
7. https://academic.oup.com/bjd/article/193/3/548/8126659
8. Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2) - PMC